Dramatic Response to Cabozantinib in a Patient with Refractory Hepatocellular Carcinoma with c-MET Amplification

We report a case of a patient with c-MET amplified hepatocellular carcinoma (HCC) who had a dramatic response to cabozantinib despite being refractory to four previous lines of systemic therapy. The patient had previously received regorafenib plus nivolumab as first-line treatment, lenvatinib as sec...

Descripción completa

Detalles Bibliográficos
Autores principales: Sang, Yun Beom, Kim, Gwangil, Hwang, Sohyun, Kang, Haeyoun, Chon, Hong Jae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: XIA & HE Publishing Inc. 2023
Materias:
Illuminating and Instructive Clinical Case
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037501/
https://www.ncbi.nlm.nih.gov/pubmed/36969903
http://dx.doi.org/10.14218/JCTH.2022.00212

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037501/
https://www.ncbi.nlm.nih.gov/pubmed/36969903
http://dx.doi.org/10.14218/JCTH.2022.00212

Ejemplares similares